NRSNW
Income statement / Annual
Last year (2024), NeuroSense Therapeutics Ltd.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, NeuroSense Therapeutics Ltd.'s net income was -$10.21 M.
See NeuroSense Therapeutics Ltd.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$22,000.00
|
$97,000.00
|
$89,000.00
|
$3,000.00
|
$3,000.00
|
$0.00
|
| Gross Profit |
-$22,000.00
|
-$97,000.00
|
-$89,000.00
|
-$3,000.00
|
-$3,000.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$5.70 M
|
$7.27 M
|
$6.42 M
|
$3.08 M
|
$2.50 M
|
$898,000.00
|
| General & Administrative Expenses |
$0.00
|
$4.78 M
|
$7.14 M
|
$2.51 M
|
$393,000.00
|
$337,000.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$4.18 M
|
$4.78 M
|
$7.14 M
|
$2.51 M
|
$393,000.00
|
$337,000.00
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$9.88 M
|
$12.05 M
|
$13.55 M
|
$5.59 M
|
$2.89 M
|
$1.24 M
|
| Cost And Expenses |
-$9.90 M
|
$12.05 M
|
$13.55 M
|
$5.59 M
|
$2.89 M
|
$1.24 M
|
| Interest Income |
$2,000.00
|
$178,000.00
|
$91,000.00
|
$0.00
|
$61,000.00
|
$18,000.00
|
| Interest Expense |
$311,000.00
|
$550,000.00
|
$15,000.00
|
$1.15 M
|
$1,000.00
|
$5,000.00
|
| Depreciation & Amortization |
$22,000.00
|
$97,000.00
|
$89,000.00
|
$3,000.00
|
$3,000.00
|
$1.24 M
|
| EBITDA |
-$9.88 M |
-$9.64 M |
-$13.38 M |
-$2.88 M |
-$2.83 M |
-$1.25 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$308,000.00
|
$769,000.00
|
$1.21 M
|
$1.55 M
|
$60,000.00
|
$13,000.00
|
| Income Before Tax |
-$10.21 M
|
-$11.28 M
|
-$12.34 M
|
-$4.04 M
|
-$2.83 M
|
-$1.22 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
-$1.14 M
|
-$1.55 M
|
$1,000.00
|
$5,000.00
|
| Net Income |
-$10.21 M
|
-$10.11 M
|
-$11.20 M
|
-$2.50 M
|
-$2.83 M
|
-$1.23 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-0.55 |
-0.83 |
-0.97 |
-1.29 |
-1.46 |
-0.63 |
| EPS Diluted |
-0.55 |
-0.83 |
-0.97 |
-1.29 |
-1.46 |
-0.63 |
| Weighted Average Shares Out |
$18.60 M
|
$13.64 M
|
$11.50 M
|
$1.94 M
|
$1.94 M
|
$1.94 M
|
| Weighted Average Shares Out Diluted |
$18.60 M
|
$13.64 M
|
$11.50 M
|
$1.94 M
|
$1.94 M
|
$1.94 M
|
| Link |
|
|
|
|
|
|
